Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ALS drug shows promise in Mid-Stage trial

NCT ID NCT06365216

Disease control Sponsor: Axoltis Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called NX210c in 80 adults with ALS, a nerve disease that weakens muscles over time. Participants receive multiple IV infusions of the drug or a placebo to see if it slows the disease and is safe. The main focus is on changes in blood markers that reflect nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥ 18 years, inclusive at screening. * Patients diagnosed as having possible, probable, probable laboratory-supported, or definite ALS according to El Escorial Revised criteria. * King's Clinical Staging Stage ≤3, disease duration of ≤ 36 calendar months Exclusion Criteria: * Patients with any cognitive or psychological disorder, intellectual disability or other significant impairment that would result in an inability to understand and sign the informed consent. * History of any clinically significant or unstable medical, neurological, psychiatric condition, disorder or disease (other than ALS) or social circumstances that, based on the investigator's judgment, would interfere with the conduct of the study or pose a risk to the patient if they were to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyotrophic lateral sclerosis

Contacts and locations

Locations

  • CHRU De Nancy

    Nancy, France, 54000, France

  • CHU de Lyon HCL

    Bron, 69500, France

  • Centre Hospitalier Et Universitaire de Limoges

    Limoges, 87042, France

  • Centre Hospitalier Regional Et Universitaire De Brest

    Brest, France, 29200, France

  • Centre Hospitalier Regional Universitaire de Tours

    Tours, 37044, France

  • Centre Hospitalier Universitaire De Bordeaux

    Bordeaux, 33000, France

  • Centre Hospitalier Universitaire De Caen Normandie

    Caen, France, 14033, France

  • Centre Hospitalier Universitaire d'Angers

    Angers, 49100, France

  • Centre Hospitalier Universitaire de Clermont-Ferrand - Hôpital Gabriel Montpied

    Clermont-Ferrand, 63003, France

  • Centre Hospitalier Universitaire de Lille

    Lille, 59037, France

  • Centre Hospitalier Universitaire de Montpellier

    Montpellier, 34295, France

  • Centre Hospitalier Universitaire de Nantes - Hôpital Nord Laennec

    Nantes, 44093, France

  • Centre Hospitalier Universitaire de Nice

    Nice, 06000, France

  • Centre Hospitalier Universitaire de Rennes

    Rennes, 35000, France

  • Hôpital La Timone - APHM

    Marseille, France, 13005, France

  • Hôpital de la Pitié Salpêtrière

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.